How we work

We constantly push ourselves in the pursuit of better – better solutions, better processes and better ways of working that help our clients navigate complexity and make better decisions with greater confidence

We recognise that the journey is often as important as the destination. We work like an extension of your team so your overall journey with us feels better

Our Values

Our culture is founded on a strong set of values that guide how we work with each other and our clients. We are a passionate team who believe in collaborative spirit and a can-do attitude. We build bold solutions and make insightful recommendations because we dig deeper and remain constantly curious, to provide positive challenge and fresh thinking.

Our Values

With a global perspective

We work with 24 of the top 25 pharmaceutical clients globally from our offices in the US and Europe

Our locations

Teams of experts

We are expert navigators helping steer our clients to more successful outcomes

Our people

Solving unique problems

We love the challenge of working on the industry's newest and most complex problems

Job openings

Expert Navigation

Explore case studies that bring to life how we’ve uncovered hidden insights, explored scientific options and helped make difficult strategic choices

Case studies
Behavioural science and the Covid-19 pandemic
Behavioural science and the Covid-19 pandemic
On Thursday 12th March 2020, the prime minister of the UK gave a speech outlining the strategy for delaying the Covid-19 pandemic[1].
Is Novartis’ RNA Therapeutic Inclisiran Poised to Displace PCSK9 Antibodies and Become the Next Blockbuster Lipid-Lowering Drug?
Is Novartis’ RNA Therapeutic Inclisiran Poised to Displace PCSK9 Antibodies and Become the Next Blockbuster Lipid-Lowering Drug?
In the last several years, RNA-targeted platforms yielded FDA/EMA approved therapies for ultra-rare metabolic and neurodegenerative diseases that address significant unmet medical needs justifying high therapeutic value ($400 to >$800k annual cost of therapy).
COVID-19 – BIOTECH DISRUPTION OR DEVASTATION?
COVID-19 – BIOTECH DISRUPTION OR DEVASTATION?
Dominating news headlines around the world, the COVID-19 pandemic is asking multiple questions that challenge current norms within every facet of day-to-day life.